The Legal 500

Twitter Logo Youtube Circle Icon LinkedIn Icon

BianchiSchwald LLC

Work +41 58 220 36 00
Fax +41 58 220 36 01
Bern, Geneva, Lausanne, Zurich

Thomas Goossens

Work +41 58 220 36 00
BianchiSchwald LLC

Work Department

Banking and Finance, Private Banking, Private Equity, Corporate and M&A.


Thomas Goossens is an expert in the fields of banking and financial law, investment funds and corporate law. He regularly advises banks, securities dealers, financial institutions and trading companies, and assists promoters, asset managers of Swiss and foreign investment funds on regulatory matters. He also advises start-ups, entrepreneurs, investors, buyers, sellers and financial sponsors in all kinds of corporate finance deals, mergers and acquisitions, private equity, refinancing and project financing transactions. He further assists clients in the drafting and negotiation of contracts and represents them before civil, criminal and administrative courts at cantonal and federal levels as well as before national and international courts of arbitration in complex disputes relating to his fields of expertise.


  • Since 2017: Partner at BianchiSchwald
  • 2012-2016: Partner at BCCC
  • 2005-2011: Associate at BCCC
  • 2005: LL.M. in Commercial & Corporate Law, King's College London
  • 2003-2004: Schellenberg Wittmer, Attorneys-at-law, Geneva
  • 2001-2002: Andersen Legal, Zurich (then Ernst & Young Legal, following the takeover of Arthur Andersen's legal activities in summer 2002)


French, English, German, Portuguese, Italian, Spanish


  • Geneva Bar Association
  • Swiss Bar Association
  • Swiss Funds and Asset Management Association (SFAMA)
  • Swiss Private Equity & Corporate Finance Association (SECA)
  • Union Internationale des Avocats (UIA)
  • Centre du droit de l’entreprise (CEDIDAC)
  • Société genevoise de droit et de legislation
  • Geneva Association of Business Law (AGDA)


  • 2001: Admitted to the Geneva Bar in 2001, authorized to practice as an attorney-at-law all over Switzerland
  • 1998: Bachelor's Law degree, University of Fribourg


Banking and finance: Geneva

Within: Banking and finance: Geneva

BianchiSchwald LLC covers regulatory, financing, investment funds and dispute resolution matters for local and internationally-based banks. Thomas Goossens assisted a global bank headquartered in the UK with the preparation of contracts guaranteeing multiple loans to foreign first-division football clubs, and Lausanne-based Thierry Amy acted for Anglo-Swiss Advisors on the framework of a FINMA application procedure for collective investment schemes’ distributor. The Swiss affiliates of BNP Paribas, Banque Bordier and Barclays Bank form part of the client roster.

[back to top]

Healthcare and life sciences

Within: Healthcare and life sciences

The practice at BianchiSchwald LLC specialises in healthcare-related real estate, financing, transactional and public procurement advice. Its client base consists of facility management companies, tech start-ups and clinics. Marc Metzger is advising Vamed and project company Rehaklinik Dussnang on the construction of a rehabilitation clinic, and Geneva-based Thomas Goossens serves as corporate counsel to Prexton Therapeutics.

[back to top]

Leading firms: French-speaking Switzerland

Within: Leading firms: French-speaking Switzerland

BianchiSchwald LLC is well known for banking and finance, corporate and M&A, employment and real estate law. Thierry Amy, Thomas Goossens, Manuel Bianchi della Porta, Stéphanie Fuld and Yves de Coulon are the names to note.

[back to top]

Back to index

Legal Developments by:
BianchiSchwald LLC

  • Latest developments in planning and zoning

    In Le Temps, the daily newspaper of reference of Western Switzerland, Yves de Coulon analyses the latest developments in the field of planning and zoning: Weber Initiative, Landscape Initiative, recent modifications of the Federal Law on planning and zoning, what consequences on the cantons' autonomy in the area of planning and zoning?
    - BCCC Attorneys-at-law LLC

Legal Developments in Switzerland

Legal Developments and updates from the leading lawyers in each jurisdiction. To contribute, send an email request to
  • Ordinance on Integrity and Transparency in the Therapeutic Products Sector has been adopted

    Click here for more information.
  • Bär & Karrer Advises B3i in its Current Equity Funding Round

    Industry-led InsurTech B3i Services AG successfully raised additional funds from current shareholders and new investors to further develop and grow its blockchain-based insurance transaction platform. B3i was founded in October 2016 as an insurance industry consortium which then formed B3i Services AG as an independent company. The shareholder group includes some of the world's largest insurers and reinsurers from across Europe, the Americas, and Asia. B3i intends to further expand its shareholder base over the next several months.
  • Bär & Karrer Continues to Grow Finance and Sports Practice with Two New Partners

    Bär & Karrer is pleased to announce that it further strengthens its Financing and Sports practices with new partners Lukas Roesler and Dr. Jan Kleiner, both of whom have worked with the firm previously.
  • Bär & Karrer Advises Novartis and Alcon on the Spin-off of Alcon

    Today, Novartis AG completed the spin-off of the Alcon eye care devices business, and Alcon Inc. debuted as independent publicly traded company. The Alcon shares were successfully listed on the SIX Swiss Exchange Ltd. and the New York Stock Exchange. They are also included in the Swiss Market Index (SMI), which comprises the 20 largest Swiss listed stocks.
  • Bär & Karrer Advises Primeo Energie and CSA Energie-Infrastructure Schweiz in Aquisition from ElĂ©t

    Primeo Energie, EOS Holding SA (EOS) and Électricité de France (EDF) have entered into a share purchase agreement relating to the purchase by Primeo Energie and EOS of the 25% interest held by EDF in Alpiq Holding SA. The purchase by Primeo Eergie and EOS will be financed through mandatory exchangeable loan agreements made by CSA Energie-Infrastruktur Schweiz (CSA) as lender, the biggest investment pool for Swiss energy infrastructure with 135 Swiss pension funds acting as investors. At maturity the mandatory exchangeable loan agreements will be converted into shares in Alpiq. Primeo Energie and EOS thereby pave the way for a Swiss shareholder structure of Alpiq.
  • Bär & Karrer Awarded Most Innovative Swiss Law Firm of the Year at the IFLR Europe Awards

    Bär & Karrer was awarded „Most innovative law firm of the year - Switzerland", the national award for Switzerland given in the IFLR European Awards. The most innovative law firm of the year award recognizes Bär & Karrer as the Swiss law firm with the best track record in 2018 giving advice on the most innovative cross-border deals covering all award practice areas. It is already the third prize of this kind in period of six years awarded to Bär & Karrer.
  • Bär & Karrer Advises DSV on Public Exchange Offer for Panalpina

    On 1 April 2019, DSV A/S, Hedehusene, Denmark and Panalpina Welttransport (Holding) AG, Zurich, Switzerland, have entered into an agreement on the terms and conditions of a combination by way of a public exchange offer by DSV for all publicly held registered shares of Panalpina for approximately CHF 4.6 billion. The board of directors of Panalpina has resolved to support the public exchange offer by DSV and to recommend the acceptance of DSV's public exchange offer to its shareholders.
  • Bär & Karrer Advises Lonza on the Entering into a Strategic Joint Venture with Chr. Hansen for Deve

    On 2 April 2019, Lonza, a leading pharma contract manufacturing company, and Chr. Hansen, a leading global bioscience company, announced that they have signed an agreement to establish a 50/50 joint venture to pioneer the live biotherapeutic products (LBPs) industry and position themselves as the leading contract development and manufacturing partner (CDMO) for biotech and pharma customers. The joint venture brings together best-in-class, complementary capabilities and will be the first CDMO globally to provide a full supply chain that offers manufacturing of bacteria strains for therapeutic use. The joint venture will be a 50/50 controlled legal entity that will operate from its headquarters in Basel (CH) and have production facilities in Denmark and Switzerland. A phased investment of approximately EUR 90 million will be deployed over three years to build cGMP-compliant pharma production capabilities. The joint venture will upgrade existing facilities in Hørsholm (DK) and equip new facilities in Basel (CH) to serve pre-clinical to phase II projects. Further facilities for phase III and commercial manufacturing will be developed as the pipeline matures. The joint venture is expected to be largely self-funding after the production set-up has been established.
  • Bär & Karrer Advises Computacenter in the Acquisition of PathWorks

    Computacenter Group, a leading European IT service provider listed on the London Stock Exchange, acquired PathWorks, a well-established hardware reseller in the Swiss market.
  • Bär & Karrer Advises Addtech in the Acquisition of a Majority in Omni Ray

    Addtech Group, a leading Swedish publicly listed technology trading group, acquired a majority stake in Omni Ray AG, a well-established Swiss trading company and service provider for automation solutions, mainly focused on industrial applications, infrastructure, transportation and medical industry. By this transaction, Addtech aims at strengthening its position in the European automation market.